V Square Quantitative Management LLC Makes New $1.31 Million Investment in IDEXX Laboratories, Inc. $IDXX

Key Points

• V Square Quantitative Management LLC opened a new stake in IDEXX in Q4, buying 1,937 shares valued at approximately $1.31 million.
• Insiders have been net sellers: Director Sophie V. Vandebroek and EVP Michael G. Erickson sold sizeable blocks in mid‑February, and insiders sold 45,957 shares worth about $29.86 million over the past 90 days (insider ownership 0.98%).
• IDEXX beat Q4 expectations (EPS $3.08 vs. $2.93 consensus), issued FY2026 EPS guidance of 14.29–14.80, and carries a MarketBeat consensus rating of "Moderate Buy" with an average price target of $772.22.

V Square Quantitative Management LLC acquired a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 1,937 shares of the company's stock, valued at approximately $1,310,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Virtus Advisers LLC bought a new position in IDEXX Laboratories during the third quarter worth $26,000. Park Place Capital Corp bought a new position in IDEXX Laboratories during the fourth quarter worth $29,000. WealthCollab LLC bought a new position in IDEXX Laboratories during the second quarter worth $30,000. J.Safra Asset Management Corp bought a new position in IDEXX Laboratories during the third quarter worth $31,000. Finally, Armstrong Advisory Group Inc. boosted its position in IDEXX Laboratories by 55.9% during the third quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company's stock worth $34,000 after purchasing an additional 19 shares during the period. 87.84% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

IDXX has been the subject of a number of research analyst reports. Weiss Ratings cut shares of IDEXX Laboratories from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Thursday, January 29th. Piper Sandler reduced their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set a "neutral" rating for the company in a research report on Monday, February 9th. Barclays reduced their target price on shares of IDEXX Laboratories from $850.00 to $800.00 and set an "overweight" rating for the company in a research report on Thursday, February 5th. BTIG Research reduced their target price on shares of IDEXX Laboratories from $830.00 to $800.00 and set a "buy" rating for the company in a research report on Tuesday, February 3rd. Finally, Wall Street Zen cut shares of IDEXX Laboratories from a "strong-buy" rating to a "buy" rating in a research report on Saturday, February 28th. Seven investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $772.22.

Insiders Place Their Bets

In related news, Director Sophie V. Vandebroek sold 1,464 shares of the business's stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $628.62, for a total value of $920,299.68. Following the completion of the transaction, the director owned 648 shares of the company's stock, valued at $407,345.76. The trade was a 69.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Michael G. Erickson sold 5,371 shares of the business's stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $627.38, for a total value of $3,369,657.98. Following the completion of the transaction, the executive vice president directly owned 12,693 shares of the company's stock, valued at approximately $7,963,334.34. This trade represents a 29.73% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 45,957 shares of company stock valued at $29,862,109 over the last 90 days. 0.98% of the stock is owned by company insiders.

IDEXX Laboratories Trading Up 3.0%

Shares of IDEXX Laboratories stock opened at $591.84 on Thursday. The firm has a 50-day moving average of $611.40 and a 200-day moving average of $657.72. The stock has a market cap of $47.01 billion, a PE ratio of 45.28, a PEG ratio of 3.46 and a beta of 1.72. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $769.98. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its earnings results on Monday, February 2nd. The company reported $3.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.93 by $0.15. The company had revenue of $1.09 billion during the quarter, compared to analysts' expectations of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. IDEXX Laboratories's quarterly revenue was up 14.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.